MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Qiagen’s COVID-19 Testing Arsenal Grows with EUA of NeuMoDx Assay

Rafael Henrique -stock.adobe.com IMG_Mar292021at100626AM.jpg
Hilden, Germany-based Qiagen inherited the test when it acquired the remaining stake in NeuMoDx Molecular for $248 million in 2020. The NeuMoDx assay's Emergency Use Authorization comes at a time when developments in COVID-19-related tests are moving at a rapid pace.

Qiagen continues to strengthen its COVID-19 testing portfolio announcing it has obtained Emergency Use Authorization for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage assay.

The Hilden, Germany-based company said the polymerase chain reaction multiplex test will be able to give simultaneous qualitative detection and differentiation of influenzas A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections within 80 minutes.

“The authorization of this new test will become a pivotal tool for the detection and differentiation of SARS-CoV-2 from influenza like illnesses or ILls,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at Qiagen. “This test will play an important role in differentiating between ILI’s while the burden of COVID-19 continues. With its ease of use and true random access, the NeuMoDx will help laboratories maintain throughput for this increased testing volume while continuing routine testing. Also, with the continued ramp-up of our manufacturing capacity, the NeuMoDx will be ready to answer the needs of molecular diagnostic laboratories for 2021 and beyond.”

Qiagen inherited the NeuMoDx assay when it acquired the remaining stake in NeuMoDx Molecular for $248 million in 2020. In 2018, Qiagen purchased a 19.9% stake in Ann Arbor, MI-based NeuMoDx Molecular.

For more info on some of Qiagen’s past COVID-19 diagnostic efforts check out this recent episode of Let’s Talk Medtech.

Developments in the COVID-19 diagnostic market have been moving at a rapid speed in the past few days.

A little more than a week ago, BioFire Diagnostics became the first company to win a nod – not EUA, but an actual FDA De Novo Designation for a COVID-19 related test.

And in a case of different industries coming together during the pandemic, Vault Health and Everly Health have formed a collaboration with DoorDash, an online food ordering and food delivery firm to distribute COVID-19-related tests.

The agreement calls for the Vault Health COVID-19 Saliva Test Kit and Everlywell COVID-19 Test Home Collection Kit DTC will be available for same-day delivery through the DoorDash marketplace app.

 

Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish